Bristol-Myers Squibb Company (BMY)

Gross profit margin

		Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Gross profit	US$ in thousands	16,531,000	16,973,000	17,713,000	15,376,000	30,745,000
Revenue	US$ in thousands	48,300,000	45,006,000	46,159,000	46,385,000	42,518,000
Gross profit margin		34.23%	37.71%	38.37%	33.15%	72.31%

December 31, 2024 calculation

Gross profit margin = Gross profit ÷ Revenue
= $16,531,000K ÷ $48,300,000K
= 34.23%

The gross profit margin of Bristol-Myers Squibb Company has exhibited fluctuations over the past five years. In 2020, the company achieved a high gross profit margin of 72.31%, indicating strong profitability from its core operations. However, there was a significant decline in 2021, with the margin dropping to 33.15%, possibly due to changes in pricing, costs, or sales mix.

Subsequently, there was a slight improvement in 2022, with the gross profit margin rising to 38.37%, but it remained below the 2020 level. In 2023 and 2024, the margin continued to decrease to 37.71% and 34.23%, respectively, reflecting ongoing challenges or shifts in the company's cost structure or revenue streams.

Overall, the declining trend in Bristol-Myers Squibb's gross profit margin over the years points towards potential issues in cost management, pricing strategies, or competitive pressures that may impact its overall profitability and financial performance. Further analysis and monitoring of these factors will be crucial for assessing the company's ability to maintain and improve its gross profit margin in the future.